Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB1801 vs docetaxel (Taxotere) in HER2-negative advanced breast cancer
CTR20263268Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of albumin-bound docetaxel in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Aug 2026; status: active.
02
Drugs
albumin-bound docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263268.